Accordingly, pharmacological recombinant fibroblast growth factor 21 therapies have been shown to counteract obesity and its related metabolic disorders in both rodents and nonhuman primates. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.